An integrated community TB-HIV adherence model provides an alternative to DOT for tuberculosis patients in Cape Town

Int J Tuberc Lung Dis. 2016 Sep;20(9):1185-91. doi: 10.5588/ijtld.15.0855.

Abstract

Setting: Cape Town, South Africa.

Objective: To evaluate anti-tuberculosis treatment outcomes and rate of antiretroviral therapy (ART) initiation using weekly community-based adherence support compared to daily directly observed therapy (DOT).

Methods: This was a retrospective analysis comparing two cohorts treated for tuberculosis (TB) in 70 TB clinics during 6-month periods before and after the introduction of a new adherence model comprising treatment literacy sessions during 2 weeks of DOT, followed by weekly home visits by community care workers to eligible patients managing their own treatment. Odds ratios (ORs) of treatment success and ART initiation were calculated using multivariable random effects logistic regression models. Hazard ratios (HRs) of default and death were calculated using multivariable random effects Cox regression models.

Results: The pre-intervention cohort comprised 11 896 patients with TB and the post-intervention cohort 11 314. There was no difference in pre- and post-intervention anti-tuberculosis treatment success rates (respectively 82.8% and 82.5%, adjusted OR [aOR] 1.02, 95%CI 0.89-1.17, P = 0.76) nor an increased hazard of death (adjusted HR [aHR] 0.98, 95%CI 0.80-1.21, P = 0.87) or default (aHR 0.97, 95%CI 0.81-1.15, P = 0.69). The ART initiation rate increased from 67% to 74% (aOR 1.43; 95%CI 1.01-1.85, P < 0.01).

Conclusion: Weekly community-based adherence support was a viable alternative to daily DOT, with no deterioration in anti-tuberculosis treatment outcomes and an increase in ART initiation.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anti-HIV Agents / therapeutic use
  • Antitubercular Agents / therapeutic use
  • Community Health Workers*
  • Directly Observed Therapy*
  • Female
  • HIV Infections / drug therapy*
  • Humans
  • Logistic Models
  • Male
  • Medication Adherence*
  • Proportional Hazards Models
  • South Africa
  • Treatment Outcome
  • Tuberculosis / drug therapy*
  • Young Adult

Substances

  • Anti-HIV Agents
  • Antitubercular Agents